Aptamers News and Research

RSS

New system makes it easier to detect rare molecules linked to early disease

By attaching specialized molecules to the backbone of DNA, researchers have made it easier to detect rare molecules associated with early disease.

20 Dec 2017

HKBU experts develop new generation of smart anti-cancer drug molecules

The toxic nature of chemotherapy poses a great challenge to clinical treatment of cancer. A team of scholars from the School of Chinese Medicine of Hong Kong Baptist University devoted their efforts to the development of a new generation of smart anti-cancer drug molecules.

15 Dec 2017

Researchers use RNA nanotechnology to program exosomes for delivering effective cancer therapies

A new study shows that attaching antibody-like RNA nanoparticles to microvesicles can deliver effective RNA therapeutics such as small interfering RNA specifically to cancer cells.

13 Dec 2017

Caris Life Sciences reveals identification of new mechanism of action to treat NHL

Caris Life Sciences, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced a data presentation, at the 59th American Society of Hematology Annual Meeting & Exposition in Atlanta, demonstrating the identification of a new mechanism of action to treat non-Hodgkin lymphoma (NHL).

13 Dec 2017

Study focuses on improving pharmacokinetic properties of therapeutic aptamers

Designing new therapeutic DNA aptamers with diverse side chains can improve their ability to interact with targets, and a new study describes characteristics of these side chains that may determine how long the aptamers remain in the bloodstream.

30 Nov 2017

Bioengineers develop brain sensor technique to understand cocaine addiction in adolescent mind

Several studies have provided strong evidence that adolescents--people in their teens to early twenties--have a higher vulnerability than adults to addictive substances like cocaine.

1 Nov 2017

Researchers isolate new molecule suitable for control of contact allergies

Researchers from the University of Bonn have isolated a molecule that is suitable for the control of contact allergies. The study illuminates a central immune mechanism, which may also play a role in other inflammatory diseases such as arthritis or arteriosclerosis.

30 Oct 2017

IBN researchers create DNA technology with two new genetic alphabets

Just like how alphabets are strung together to form words, our DNA is also strung together by alphabets to encode proteins. Our DNA contains only 4 natural genetic alphabets - A, C, G and T, which hold the blueprint for the production of proteins that make our bodies work.

26 Oct 2017

Researchers take first steps towards development of biosensor for detection of bacteria

Researchers from UPM have taken the first steps towards the development of a sensor for the detection of bacterial meningitis in real time by combining gravimetric sensors with synthetic antibodies giving, as a result, a sensitive, rapid and affordable method.

15 Sep 2017

Nexmos, Base Pair Biotechnologies create new class of DNA-aptamer based oxidation inhibitors

Base Pair Biotechnologies, Inc., The Aptamer Discovery Company, and Nexmos, Inc., the Aptamer Application R&D Company, announce the creation of a new class of DNA-aptamer based oxidation inhibitors.

30 Dec 2016

Protein-based CHD risk score developed

Researchers have screened over 1000 plasma proteins to develop a predictive score in patients with stable coronary heart disease.

22 Jun 2016

Scientists provide overview of most promising compounds to combat prostate cancer

Scientists from MIPT (Moscow Institute of Physics and Technology), MSU (Moscow State University), and National University of Science and Technology “MISIS” provided an overview of the most promising compounds which can be used as medications for prostate cancer.

23 Mar 2016

University of Oxford, SomaLogic partner to discover protein biomarkers for clinical diseases and conditions

The University of Oxford and SomaLogic announced today that they have agreed to undertake a number of collaborative projects that will employ SomaLogic's proprietary SOMAmer reagents and SOMAscan assay technologies to discover and characterize protein biomarkers for a range of clinical diseases and conditions.

8 Feb 2016

New sensor can detect estrogen levels in liquids

Estrogen is a tiny molecule, but it can have big effects on humans and other animals. Estrogen is one of the main hormones that regulates the female reproductive system - it can be monitored to track human fertility and is sometimes administered to livestock like cows and sheep to control the reproductive cycle.

25 Nov 2015

Replacing animal-derived antibodies with modern technologies can improve quality of research, reduce costs

Time, money, and tens of thousands of animals could be saved if researchers replace animal-derived antibodies with modern technologies, according to a review by the PETA International Science Consortium Ltd. published today in Biotechnology Advances, a peer-reviewed journal covering developments and trends in biotechnology principles and applications.

27 Oct 2015

UC researcher awarded NCI grant to study effect of MED1 protein on HER2-positive breast cancer

Xiaoting Zhang, PhD, associate professor in the Department of Cancer Biology at the University of Cincinnati College of Medicine, has received a $1.8 million, five-year, R01 award (R01CA197865) from the National Cancer Institute to continue breast cancer research focusing on the function of the protein MED1 on HER2-positive breast cancer.

8 Jul 2015

New light-triggered strategy can provide accurate control over aptamer-based therapeutics

While aptamers—single-stranded nucleic acids—offer promise as drug-delivery tools for cancer treatment, it has proven difficult to get them to tumor cells at therapeutic levels.

4 Dec 2014

Celsion signs definitive asset purchase agreement to acquire EGEN

Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA.

10 Jun 2014

Researchers find new technique to detect just a handful of lurking tumor cells

Beating cancer is all about early detection, and new research from the University of South Carolina is another step forward in catching the disease early. A team of chemists is reporting a new way to detect just a handful of lurking tumor cells, which can be outnumbered a billion to one in the bloodstream by healthy cells.

28 Feb 2014

NOXXON Pharma reports interim data from two phase IIa studies of anti-CXCL12/SDF-1 Spiegelmer NOX-A12

NOXXON Pharma disclosed interim data from two independent clinical phase IIa studies of the anti-CXCL12/SDF-1 Spiegelmer olaptesed pegol (NOX-A12) at the 55th annual meeting of the American Society of Hematology in New Orleans, LA, USA from 7-10 December 2013.

9 Dec 2013